“I’m a competitive guy. Anyone who knows me will tell you I can’t stand to lose. I’ve never faced anything on the racetrack as tough as childhood cancer. But I won’t stop until I beat it.”
— Jeff Gordon
Every year worldwide, 300,000 children and adolescents will have to fight cancer. Due to the lack of treatments specifically designed and developed for children, one in five will not beat the disease, and many will suffer the long-term side effects from the current therapies.
Oncoheroes Biosciences, a mission-driven biotech company currently building a multiasset pipeline of childhood cancer drugs, is very excited to announce an investment from Jeff Gordon Children’s Foundation (JGCF), marking the first time JGCF has invested in a biotech company.
“We appreciate the innovative approach Oncoheroes is undertaking to develop much-needed therapies specifically to improve outcomes for kids fighting cancer,” said Dr. Jeffrey Chell, Board Chair for JGCF. “This kind of fresh thinking and expansive collaboration has the power to fuel exciting progress in childhood cancer research.”
JGCF was founded in 1999 by four-time NASCAR Cup Series champion Jeff Gordon. Since then, JGCFhas donated nearly $22 million to hospitals and children’s health organizations to primarily support pediatric cancer research.
“We are delighted to welcome and thank Jeff Gordon Children’s Foundation for joining our project. We are thrilled to see another non-profit going one step further and adopting a venture philanthropy approach by investing in Oncoheores. We believe this is a unique opportunity for the childhood cancer community to be in the driver seat in bringing new therapies for childhood cancer,” explained Ricardo Garcia, co-founder, and CEO of Oncoheroes Biosciences.
